aminodihydrophthalazinedione | 88976-67-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二氮杂萘
• 英文名称: aminodihydrophthalazinedione
• 英文别名: phthalhydrazide nitrogen；2-Amino-2,3-dihydrophthalazine-1,4-dione；3-amino-2H-phthalazine-1,4-dione
• CAS: 88976-67-4
• 化学式: C₈H₇N₃O₂
• 分子量: 177.162
• InChiKey: GAKDOEJMVPAICM-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.1
• 重原子数：
  13
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  75.4
• 氢给体数：
  2
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  aminodihydrophthalazinedione 在 N,N'-二环己基碳二亚胺 作用下， 以 乙醇 、 N,N-二甲基甲酰胺 为溶剂， 反应 1.0h， 生成 邻苯二甲酰肼
  参考文献：
  名称：

  Jeon, Dong Ju; Shin, Sung Chul; Lee, Youn Young, Heterocycles, 1997, vol. 45, # 11, p. 2101 - 2104

  摘要：

  DOI：

文献信息

• Preparation of prodrugs for selective drug delivery
  申请人：Mills L. Randell

  公开号：US20050080260A1

  公开（公告）日：2005-04-14

  Synthesis of a chemical compound having the formula A-B-C that may serve for applications such as drug delivery where A is a chemiluminescent, moiety, B is a photochromic moiety, and C is a biologically active moiety where A-B-C may serve as a prodrug. Novel synthetic methods of the present invention to form the prodrug comprised the steps of (1) forming a benzophenone, (2) forming a diaryl ethylene, (3) attaching a phthalimide moiety to at least one of the aryl groups of the ethylene to form a phthalimide-ethylene conjugate, (4) condensing two ethylene-phthalimide conjugates to form a phthalimide-pentadiene conjugate, (5) converting the phthalimide to the phthalhydrazide by reaction with hydrazine to form a carrier compound according to the present invention, and (6) reacting the carrier compound with an nucleophilic moiety of the drug to form the corresponding prodrug. Alternatively the carrier can be prepared by using the halo-substituted diaryl ethylene to make the corresponding cationic leuco dye-like compound with known methods. The cationic compound then is protected by reacting with a nucleophile and coupled with the aminophathalimide by palladium-catalyzed amination to form the protected phthalimide-pentadiene conjugate. The latter is refluxed with hydrazine to convert its phthalimide to the phthalhydrazide and acidified to give the carrier. An additional aspect of the present invention relates to the use of these compounds as antiviral agents for the treatment of viral infections such as HIV and as anticancer agents for the treatment of cancers such as bowel, lung, and breast cancer.

  合成具有A-B-C化学式的化合物，可用于药物传递等应用，其中A是化学发光基团，B是光致变色基团，C是生物活性基团，其中A-B-C可作为前药。本发明的新型合成方法用于形成前药，包括以下步骤：(1)形成苯酮，(2)形成二芳基乙烯，(3)将邻苯二甲酰亚胺基团连接到乙烯的至少一个芳基上，形成邻苯二甲酰亚胺-乙烯共轭物，(4)缩合两个乙烯-邻苯二甲酰亚胺共轭物，形成邻苯二甲酰亚胺-戊二烯共轭物，(5)通过与肼反应将邻苯二甲酰亚胺转化为邻苯二酰肼，形成本发明的载体化合物，(6)将载体化合物与药物的亲核基团反应，形成相应的前药。另外，可以通过使用卤代二芳基乙烯制备相应的阳离子类似的类似类似染料化合物。然后，通过与亲核试剂反应保护阳离子类似化合物，并通过钯催化的胺化与氨基邻苯二甲酰亚胺偶联，形成保护的邻苯二甲酰亚胺-戊二烯共轭物。后者与肼回流，将其邻苯二甲酰亚胺转化为邻苯二酰肼，并酸化以得到载体。本发明的另一个方面涉及将这些化合物用作抗病毒剂，用于治疗病毒感染，如HIV，以及用作抗癌剂，用于治疗结肠癌、肺癌和乳腺癌等癌症。
• CHEMICAL METHOD OF PRODUCING SMTP GROUPS OR SMTP-7 AND INTERMEDIATES USED IN THE METHOD
  申请人：Showa University

  公开号：US20200140450A1

  公开（公告）日：2020-05-07

  The present invention provides a compound having a dihydropyran structure, a method of producing a compound having a dihydropyran structure, a method of producing Pre-SMTP, a method of producing a group of SMTPs, and a pharmaceutical composition. The compound having a dihydropyran structure can be a useful intermediate in the chemically producing a group of Pre-SMTP and SMTP. Specifically, the compound having a dihydropyran structure is represented by formula (1), wherein: R 3 Si is a silyl group selected from TMS: trimethylsilyl, TES: triethysilyl, TBS (TBDMS): tert-butyldimethylsil, TIPS: triisopropylsilyl, TBDPS: tert-butyldiphenylsilyl, X is selected from COOH, CHO, and —CH═C(HCH 3 )—(CH 2 ) 2 —CH═C(CH 3 ) 2 .

  本发明提供了一种具有二氢吡喃结构的化合物，一种制备具有二氢吡喃结构的化合物的方法，一种制备Pre-SMTP的方法，一种制备一组SMTP的方法以及一种制药组合物。具有二氢吡喃结构的化合物可以作为在化学上制备一组Pre-SMTP和SMTP的有用中间体。具体来说，具有二氢吡喃结构的化合物由式(1)表示，其中：R3Si是从TMS：三甲基硅基，TES：三乙基硅基，TBS（TBDMS）：叔丁基二甲基硅基，TIPS：三异丙基硅基，TBDPS：叔丁基二苯基硅基中选择的硅基，X从COOH，CHO和—CH═C(HCH3)—(CH2)2—CH═C(CH3)2中选择。
• CRYSTALLINE FORMS FOR 5-AMINO-2, 3-DIHYDROPHTHALAZINE-1, 4-DIONE SODIUM SALT, PHARMACEUTICAL PREPARATIONS CONTAINING THE SAME AND METHOD FOR THE PRODUCTION OF SAID FORMS
  申请人：Breu Josef

  公开号：US20120329801A1

  公开（公告）日：2012-12-27

  The invention relates to the provision of two novel crystalline forms I and II for 5-amino-2,3-dihydrophthalazine-1,4-dione sodium salt. Surprisingly, it was discovered that form I and form II have differing immunological effects. This advantageous property is useful for immunospecific applications. In addition, both forms have advantageous physicochemical properties, which are useful in the production, further processing and/or use of a pharmaceutical preparation of form I or form II or a mixture of both.

  本发明涉及为5-氨基-2,3-二氢鞣酸1,4-二酮钠盐提供两种新的晶体形式I和II。令人惊讶的是，发现I和II形式具有不同的免疫学效果。这种有利的性质对于免疫特异性应用非常有用。此外，这两种形式具有有利的物理化学性质，对于制备、进一步加工和/或使用I或II形式或两者的混合物的制药制剂非常有用。
• NEW METHOD FOR OBTAINING 5-AMINO 2,3-DIHYDROPHTHALAZINE-1,4-DIONE ALKALI METAL SALTS AND THEIR USE IN MEDICINE
  申请人：Abidov Admir Musaevich

  公开号：US20110275642A1

  公开（公告）日：2011-11-10

  The invention is related to a method for preparing 5-amino-2,3-dihydrophthalazine-1,4-dione salt with alkali metals of the formula II wherein 5-nitro-2,3-dihydrophthalazine-1,4-dione is solved in water solution of MOH1 where M has the below mentioned meaning, with formation of solution of 5-nitro-2,3-dihydrophthalazine-1,4-dione alkali metal salt, which is catalytically transformed into 5-amino-2,3-dihydrophthalazine-1,4-dione salt at the temperature 40-900C by means of hydrogen under the pressure 1-4 MPa in at the presence of a transition metal catalyst (Pt, Pd) on activated carbon, and separation of crystalline 5-amino-2,3-dihydrophthalazine-1,4-dione salt is performed by water solution diluting with lower alcohol or cyclic lower ether with cooling to the temperature −5° C. to −15° C., providing that there is used 5-nitro-2,3-dihydrophthalazine-1,4-dione formed in the reaction of anhydride of 3-nitrophthalic acid with hydrazine hydrate in anhydrous acetic acid at the temperature 100-110° C. with distilling the mixture of acetic acid and water off. There was also presented a pharmaceutical composition containing such obtained 5-amino-2,3-dihydrophthalazine-1,4-dione salt with alkali metals and its application in medicine. There was also presented new use of 5-amino-2,3-dihydrophthalazine-1,4-dione sodium salt for production of a drug for treatment of heart diseases, pancreas diseases and diabetes as well as application of sodium salt optionally in combination with lithium salt for treatment of the nervous system diseases. Besides, the methods of treatment of these diseases were also presented. Formula II where M represents Li, Na, K

  该发明涉及一种制备式II的碱金属5-氨基-2,3-二氢酞嗪-1,4-二酮盐的方法，其中5-硝基-2,3-二氢酞嗪-1,4-二酮溶于MOH1的水溶液中，其中M具有下面所述的含义，形成5-硝基-2,3-二氢酞嗪-1,4-二酮碱金属盐的溶液，该溶液在存在过渡金属催化剂（Pt，Pd）和活性炭的条件下，在温度40-900C下通过氢气催化转化为5-氨基-2,3-二氢酞嗪-1,4-二酮盐，在冷却至温度-5°C至-15°C的情况下，通过将水溶液稀释至低级醇或环状低级醚中，分离出结晶的5-氨基-2,3-二氢酞嗪-1,4-二酮盐，前提是在无水乙酸中，通过3-硝基苯甲酸酐与肼水合物的反应，在温度100-110°C下蒸馏掉乙酸和水的混合物中形成5-硝基-2,3-二氢酞嗪-1,4-二酮。还提供了含有所获得的碱金属5-氨基-2,3-二氢酞嗪-1,4-二酮盐的制药组合物及其在医学上的应用。还提供了5-氨基-2,3-二氢酞嗪-1,4-二酮钠盐用于治疗心脏疾病、胰腺疾病和糖尿病的药物的新用途，以及钠盐与锂盐的组合治疗神经系统疾病的应用。此外，还提供了治疗这些疾病的方法。其中M代表Li，Na，K。
• Triprenyl phenol compound, process for production of triprenyl phenol compound, and thrombolysis enhancer
  申请人：Hasumi Keiji

  公开号：US20090216028A1

  公开（公告）日：2009-08-27

  The present invention provides a triprenyl phenol compound represented by the following formula (II) and (III) and having a thrombolysis-enhancing activity, and an efficient method for producing the triprenyl phenol compound. In formula (II) and (III), R 1 represents an aromatic group having as a substituent or as a part of a substituent at least one member selected from the group consisting of a carboxyl group, a hydroxyl group, a sulfonic acid group and a secondary amino group, or an aromatic group which comprises a secondary amino group and may comprise nitrogen; R 4 in the general formula (III) represents an aromatic amino acid residue represented by the general formula (III-1) below; X represents —CHY—(CH 3 ) 2 Z; and Y and Z are respectively —H or —OH or together form a single bond: (III-1) wherein R 5 represents a hydroxyl group which may be present or absent; and n represents an integer of 0 or 1.

  本发明提供了一种由以下化学式（II）和（III）所代表的三倍萜酚化合物，具有增强溶栓活性，以及一种高效制备该三倍萜酚化合物的方法。在化学式（II）和（III）中，R1代表芳香基团，其作为取代基或取代基的一部分至少包括羧基、羟基、磺酸基和二级氨基组成的群中的一种，或者是包含二级氨基并可能包含氮的芳香基团；在通式（III）中，R4代表由通式（III-1）所表示的芳香氨基酸残基；X代表—CHY—（CH3）2Z；Y和Z分别为—H或—OH或形成单键：（III-1）其中，R5代表可能存在或不存在的羟基；n代表0或1的整数。